Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension
作者:Whitney L. Petrilli、Scott B. Hoyt、Clare London、Daniel McMasters、Andreas Verras、Mary Struthers、Doris Cully、Thomas Wisniewski、Ning Ren、Charlene Bopp、Andrea Sok、Qing Chen、Ying Li、Elaine Tung、Wei Tang、Gino Salituro、Ian Knemeyer、Bindhu Karanam、Joseph Clemas、Gaochao Zhou、Jack Gibson、Carrie Ann Shipley、Douglas J. MacNeil、Ruth Duffy、James R. Tata、Feroze Ujjainwalla、Amjad Ali、Yusheng Xiong
DOI:10.1021/acsmedchemlett.6b00455
日期:2017.1.12
Herein we report the discovery and hit-to-lead optimization of a series of spirocyclic piperidine aldosterone synthase (CYP11B2) inhibitors. Compounds from this series display potent CYP11B2 inhibition, good selectivity versus related CYP enzymes, and lead-like physical and pharmacokinetic properties.
在本文中,我们报告了一系列螺环哌啶醛固酮合酶(CYP11B2)抑制剂的发现和领先优势。该系列化合物显示出有效的CYP11B2抑制作用,相对于相关CYP酶的良好选择性以及类似铅的物理和药代动力学特性。